How Carsten Thiel Leads In Finding a Solution to Combat the Spread of Coronavirus

October 15, 2020
0 comments
Craig Fischer
Posted in Business
0

Coronavirus is the latest threatening outbreak announced by CDC, Center for Disease Control and Prevention. The pandemic has become a global concern due to its high spreading rate. Even though both humans and animals have coronaviruses, they rarely spread to each other. By extension, people have different stories regarding the origin of the viruses that have brought the global economy to a standstill. The fact is that COVID-19 is a transmitted respiratory disease spreading between persons.

Health experts, including Carsten Thiel, continue to burn the midnight oil in pursuit of coming up with a vaccine. It’s still a challenge to differentiate whether a patient has a common cold or COVID-19 without proper testing. Shortness of breath, fever, and cough are the crucial symptoms of coronavirus that show up approximately two weeks of exposure.

Furthermore, many people seem to throw caution into the wind, thus, watering down the efforts made in bringing down the infection. Thiel also notes that providing drugs to pharmacies and hospitals and price regulation is a delicate topic that needs a professional approach.

The History and Global Impact of the Pandemic

According to Thiel and other experts, people that travel a lot internationally risk contacting the coronavirus. A lot had happened since December 2019, when China reported the first case in Wuhan, Hubei province. By February 25, 2020, approximately 2,462 people had died. The beauty is that thousands have recovered through managing the virus because it has no cure yet. Most countries have proved that people catch coronavirus through the respiratory system.

Coronavirus Containment Measures

However, the United Kingdom and some European countries have experienced a confusing transmission chain that has resulted in a high number of infections and deaths. Governments have imposed measures as Carsten Thiel and other stakeholders identify a lasting solution. Isolation, social distancing, personal hygiene, especially washing of hands, and closing public gatherings are among the health guidelines.

How Pharmaceutical Companies Have Helped In Combating COVID-19

According to Carsten Thiel, many Pharmaceutical companies have joined hands in finding a vaccine for the deadly virus. However, the European commercialization company, EUSA Pharma president fears that approximately 40 to 60% of the socially active population risks catching the virus. Thiel is optimistic that numerous people would develop a strong immunity to fight the coronavirus when the experts come up with a vaccine.

On the other hand, Thiel and other CEOs of renowned pharmaceuticals in the United States have collaborated with President Trump to speed up getting a vaccine. Carsten further admits that Pharma companies have a significant challenge in getting a quick preventive solution to thousands of infected people globally.

Janssen Pharmaceutical Companies have collaborated with Johnson & Johnson in fighting the 2019-nCov strain of the coronavirus through vaccines and antiviral therapies in America. The process would benefit both the current and future COVID-19 patients significantly. In other words, they would study the physiological paths of the virus thoroughly to build a lasting solution.

European companies, including APEIRON Biologics from Vienna, Austria, are developing cancer immunotherapies. The firm collaborates with EUSA Pharma Ltd in the marketing of APN311 that treats pediatric neuroblastoma, among other award-winning achievements. Its currently working on trials of a respiratory product to treat COVID-19 in China. Concisely, Carsten Thiel believes that the mentioned companies’ efforts would soon reduce the spread.

Carsten Thiel’s Medical Background

The President of EUSA started his career at Abeana Therapeutics, Inc. as the CEO based in Alexion before moving to Amgen in charge of the European region. The Ph.D. in Biochemistry and Molecular Biology holder has the expertise of nearly three decades in the pharmaceutical industry, specifically in rare diseases and oncology.